BioXcel Therapeutics, Inc. Common Stock
BTAIBioXcel Therapeutics, Inc. (BTAI) is a biotechnology company focused on the development and commercialization of artificial intelligence-driven therapies for neuroscience and immuno-oncology indications. The company utilizes its proprietary platform to identify and develop innovative drug candidates, aiming to address unmet medical needs in areas such as acute neuropsychiatric disorders and cancer.
Company News
A proposed class action settlement of $9,750,000 has been approved by the United States District Court for the District of Connecticut on behalf of purchasers of BioXcel Therapeutics securities between March 9, 2023 and June 28, 2023. A hearing is scheduled for September 2, 2026 to determine if the settlement is fair and reasonable. Class members...
BioXcel Therapeutics announced a registered direct offering of 4.5 million shares of common stock and accompanying warrants at $1.739 per share, raising approximately $8.0 million in gross proceeds. The company also agreed to reduce exercise prices on previously issued warrants held by the investor. The offering is expected to close on March 11, ...
BioXcel Therapeutics will ring the Nasdaq Closing Bell to celebrate its breakthrough progress in treating agitation associated with bipolar disorders and schizophrenia, highlighting the successful completion of its SERENITY At-Home pivotal trial.
BioXcel Therapeutics announced it has regained compliance with Nasdaq's market value listing requirements after previously being notified of non-compliance in March 2025.
BioXcel Therapeutics reported positive results from its SERENITY At-Home Phase 3 trial for BXCL501, demonstrating safety and potential for at-home treatment of agitation in bipolar and schizophrenia patients. The company plans to submit a supplemental New Drug Application (sNDA) in Q1 2026.
